MedTrace Logo

The Effects of Intake of Protein From Cod Fillet and Cod Residual Material on Lipid Regulation, Glucose Regulation and Inflammation in Overweight or Obese Adults.

NCT03538821 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-01-04

No results posted yet for this study

Summary

A high intake of fish is associated with positive health effects, including prevention and treatment of chronic non-communicable diseases, such as cardiovascular diseases (CVDs) and type 2 diabetes. These health effects have traditionally been attributed to the omega-3 fatty acids in fatty fish, but recent studies have suggested that also fish proteins may improve biomarkers of metabolic disease. Intake of cod fillet have previously shown beneficial effects on blood lipids, glucose regulation and body composition in adults with overweight or obesity. Health effect of cod residual material from fillet production (i.e., head, backbone, skin, cutoffs and entrails) have so far not been investigated, but residuals from other fish species have shown promising effects on glucose regulation in rats. The main aim of the current study is to investigate the effects of protein from cod fillet and cod residuals on serum lipids, glucose regulation and inflammatory markers in healthy overweight or obese adults.

Conditions

  • Overweight and Obesity
  • Healthy

Interventions

DIETARY_SUPPLEMENT

Intact cod protein from fillet

Intact cod protein from fillet 8 g protein daily for 8 weeks

DIETARY_SUPPLEMENT

Intact cod protein from residual material

Intact cod protein from residual material, 8 g protein daily for 8 weeks

DIETARY_SUPPLEMENT

Control

Control group receive tablet containing fillers

Sponsors & Collaborators

  • The Research Council of Norway

    collaborator OTHER

  • K. Halstensen AS

    collaborator UNKNOWN

  • Regional Research Fund Western Norway

    collaborator UNKNOWN

  • Nofima

    collaborator OTHER

  • University of Bergen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-12-31
Completion
2021-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03538821 on ClinicalTrials.gov